Clinical Trials
51 trialsSTARTRK-2
Hoffmann-La Roche
TRIDENT-1
Turning Point Therapeutics, Inc.
INDIGO
Boston Scientific Corporation
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
BRAVESST2
Crinetics Pharmaceuticals Inc.
REAL-LU
Novartis
KinLET
ITM Solucin GmbH
NETTER-3
Novartis
CAREFNDR
Crinetics Pharmaceuticals Inc.
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Ipsen
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
STELLAR-311
Exelixis
ALPHAMEDIX02
Orano Med LLC
DeLLphi-307
Amgen
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
COMPETE
ITM Solucin GmbH
ACTION-1
RayzeBio, Inc.
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA Inc
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NETTER-P
Advanced Accelerator Applications
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
ODYSSEY
Guerbet
NETTER-2
Advanced Accelerator Applications
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
SALUS
Advanced Accelerator Applications
LUTATHERA Injection General Use Result Survey
Novartis
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
OXTEND-01
Debiopharm International SA
RegisterNET
Wren Laboratories LLC
SORENTO
Camurus AB
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
COMPOSE
ITM Solucin GmbH
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Ariceum Therapeutics GmbH
Open-Label Surufatinib in European Patients With NET
Hutchmed
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC